Edit
Vtesse
http://www.vtessepharma.com/Last activity: 03.04.2017
Probably Closed - Reference to Mallinckrodt Pharmaceuticals
Biotech company built around a Phase 2/3 ready asset from NIH / NCATS, cyclodextrin, for the treatment of Niemann-Pick C (NPC)
Total raised: $42M
Investors 2
| Date | Name | Website |
| - | New Enterp... | nea.com |
| - | Bay City C... | baycitycap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.07.2016 | Series A | $17M | - |
| 07.01.2015 | Series A | $25M | - |
Mentions in press and media 14
| Date | Title | Description |
| 03.04.2017 | Cydan Development Announces the Acquisition of Its First Rare Disease Spin-out, Vtesse, Inc. by Sucampo Pharmaceuticals, Inc. | Link to Release Cambridge, Mass., April 3, 2017 – Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improve the lives of people living with rare genetic diseases, today announces that Vtesse, Inc., ... |
| 03.04.2017 | Sucampo Pharmaceuticals Acquires Vtesse, for $200M | Vtesse, Inc., a Gaithersburg, Maryland-based rare disease company, has been acquired by Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), for an upfront consideration of $200m. Sucampo funded the acquisition through the issuance of 2,782,678 sh... |
| 29.11.2016 | Vtesse Receives Rare Pediatric Disease Designation for VTS-270 for the Treatment of Niemann-Pick Type C1 Disease | Gaithersburg, MD — Vtesse, Inc., a company committed to developing medicines to benefit patients with ultra rare, life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease des... |
| 11.10.2016 | Cydan Announces the Promotion of James McArthur, Ph.D. to President, Research and Development | Cambridge, MA — Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improve the lives of people living with rare genetic diseases, announced the promotion of James McArthur, Ph.D. to president, research ... |
| 26.07.2016 | Vtesse Secures Additional $17M in Series A Extension | Gaithersburg, MD – Vtesse, Inc. a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, announced today that it has secured $17 million in additional Series A funding in support of ... |
| 25.07.2016 | Vtesse Secures Additional $17 Million in Series A Extension | Vtesse, Inc., a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, announced today that it has secured $17 million in additional Series A funding in support of its global, pivota... |
| 25.07.2016 | Vtesse Inks Additional $17M Series A Extension | GAITHERSBURG, MD, Company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, has secured $17 million in additional Series A funding. >> Click here for more funding data on Vtess... |
| 25.07.2016 | Vtesse Secures $17M in Series A Funding | Vtesse, Inc., a Gaithersburg, Md.-based developer of drugs that will benefit patients with extremely rare, life-threatening diseases, secured $17m in additional Series A funding. Backers included Alexandria Venture Investments, Bay City Cap... |
| 14.04.2016 | Cydan Raises $31M in Series A Funding | Cambridge, MA — Cydan Development, Inc., an orphan drug accelerator dedicated to creating therapies that improves the lives of people living with rare genetic diseases, today announced the launch of Imara, Inc. This is the second orphan dru... |
| 19.08.2015 | Rare disease companies must compete for clinical trial participants | This could be a real blow for patient communities, who have been the driving force behind bringing rare disease to the attention of biopharma companies. “This is a critical juncture for our community,” Nadine Hill, executive director of the... |
Show more